STOCK TITAN
  1. Home
  2. Sec-filings
  3. HURA
  4. [8-K] TuHURA Biosciences, Inc./NV Reports Material Event

TuHURA Biosciences (Nasdaq: HURA) adds $50M credit line and IFx-2.0 royalty

Filing Impact
(High)
Filing Sentiment
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

TuHURA Biosciences, Inc. entered into a Loan Agreement with Parkview Holdings One LLC, an affiliate of its largest stockholder, establishing a $50 million revolving credit facility maturing on April 21, 2031. The facility bears 12% annual interest, rising by an additional 6% during events of default, and is secured by substantially all assets of the company and its subsidiaries.

TuHURA may draw once per month, up to the greater of $1.7 million or the agreed budgeted monthly expenses, with unused capacity rolling forward. Subject to stockholder approval of related share issuances, the company expects this facility to fund operations and development programs into the first quarter of 2028. In connection with the loan, Parkview receives a low to mid‑single digit royalty on annual Net Sales of IFx‑2.0‑based products up to $450 million per year, and the agreement imposes customary covenants and change‑of‑control conversion rights.

Positive

  • $50 million revolving credit facility is expected to fund TuHURA’s operations and development programs, including IFx‑2.0 and TBS‑2025, into the first quarter of 2028, reducing near‑term financing uncertainty.

Negative

  • The facility carries a relatively high 12% annual interest rate, rising by an additional 6% on default, is secured by substantially all assets, and is paired with a royalty on IFx‑2.0 Net Sales, increasing the long‑term economic burden on the company’s lead program.
  • The lender is an affiliate of TuHURA’s largest stockholder with potential board appointment and conditional equity conversion rights, creating conflict‑of‑interest and governance considerations for investors.

Insights

$50M insider credit line extends TuHURA’s cash runway but at a high cost.

TuHURA secured a $50 million revolving credit facility from an affiliate of its largest shareholder. The loan carries a 12% interest rate, rising by 6% on default, and is secured by substantially all company assets. Management states this should fund operations into the first quarter of 2028.

The agreement limits new debt, investments, dispositions and restricted payments, and includes a repayment feature where 75% of net profits from two consecutive profitable quarters must go to principal. A low to mid‑single digit royalty on IFx‑2.0 Net Sales up to $450 million per year adds ongoing economic burden on the lead asset.

Because the lender is related to the largest stockholder and may gain board representation and conditional equity conversion rights at $2.662 per share upon a qualifying change of control, governance and conflict‑of‑interest risk exist alongside the funding benefit.

Item 1.01 Entry into a Material Definitive Agreement Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Item 3.02 Unregistered Sales of Equity Securities Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 7.01 Regulation FD Disclosure Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01 Financial Statements and Exhibits Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Revolving credit facility size $50 million Maximum loan availability under Loan Agreement with Parkview
Interest rate 12% per annum Base interest on outstanding borrowings, plus 6% during default
Default interest step-up Additional 6% per annum Applies if an event of default is continuing
Monthly minimum draw cap $1.7 million Minimum of the monthly borrowing limit, compared against budgeted expenses
Runway guidance Into Q1 2028 Expected funding horizon from the facility, subject to stockholder approval of Loan Fee Shares
Royalty Net Sales cap $450 million per year Annual Net Sales threshold to which IFx‑2.0 royalty percentage applies
Profit-based principal sweep 75% of net profits Repayment share if profitable for two consecutive quarters from product sales
Conversion price $2.662 per share Price for Parkview’s conditional conversion right upon a qualifying Change of Control
revolving credit facility financial
"Parkview agreed to extend a $50 million revolving credit facility to the Company"
A revolving credit facility is a type of loan that a business can borrow from whenever it needs money, up to a set limit. It’s like having a credit card for companies—allowing them to borrow, pay back, and borrow again as needed, providing flexibility for managing cash flow or funding short-term expenses.
Net Sales financial
"The royalty will be equal to a percentage of “Net Sales” of Products up to $450 million"
Net sales is the total money a company earns from selling its goods or services after subtracting returns, discounts, and allowances — like a store counting the cash it actually keeps after refunds and coupons. Investors use net sales to gauge true customer demand and the real size of a business’s revenue stream, since it forms the basis for profit margins, growth trends, and comparisons between companies.
Change of Control financial
"in the case of a change of control of the Company in which a person or entity acquires 51% or more"
A change of control occurs when the ownership or management of a company shifts significantly, such as through a sale, merger, or acquisition, resulting in new leadership or ownership structure. This change can impact the company's direction and decision-making, which is important for investors because it may affect the company's stability, strategy, and future prospects.
emerging growth company regulatory
"405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ... Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
accredited investors regulatory
"Conversion Shares will be issued solely to “accredited investors,” as such term is defined in the Securities Act of 1933"
Accredited investors are individuals or entities considered to have enough financial knowledge and resources to understand and handle more complex and risky investments. They are often allowed to participate in private investment opportunities that are not available to the general public, similar to how experienced players might access exclusive clubs or events. This status helps ensure that investors can manage potential risks and rewards appropriately.
events of default financial
"The Loan Agreement also contains customary events of default, which include the occurrence of a Change of Control"
Events of default are specific breaches or failures listed in a loan, bond, or credit agreement that give lenders the right to act, such as demanding immediate repayment, raising interest rates, or taking secured assets. They matter to investors because triggering one is like setting off a financial alarm: it raises the chance of foreclosure, restructuring, or bankruptcy and can sharply reduce the value of a company’s stock or bonds and increase borrowing costs.
Understanding 8-K Material Events →
TuHURA Biosciences, Inc./NV NASDAQ false 0001498382 0001498382 2026-04-21 2026-04-21
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 21, 2026

 

 

TUHURA BIOSCIENCES, INC.

(Exact name of Registrant as Specified in Its Charter)

 

 

 

Nevada   001-37823   99-0360497

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

10500 University Center Dr., Suite 110

Tampa, Florida 33612

(Address of Principal Executive Offices, including zip code)

Registrant’s Telephone Number, Including Area Code: (813) 875-6600

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 


Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.001 par value per share   HURA   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 1.01

Entry into a Material Definitive Agreement.

On April 21, 2026, TuHURA Biosciences, Inc. (the “Company”) entered into a Loan Agreement (the “Loan Agreement”) with Parkview Holdings One LLC, as lender (“Parkview”), under which Parkview agreed to extend a $50 million revolving credit facility to the Company upon the terms and conditions set forth in the Loan Agreement. The Company intends to use borrowings under the Loan Agreement for general corporate purposes, including the funding of the Company’s ongoing clinical trials and development programs. Parkview is an affiliate of the Company’s largest stockholder, K&V Investment One LLC (owned by Vijay Patel).

The Loan Agreement provides for a revolving credit facility that matures on April 21, 2031, with a maximum amount of loan availability of $50 million. Borrowings under the Loan Agreement are secured by substantially all of the assets of the Company and its subsidiaries and will bear interest at a rate of twelve percent (12%) per annum (plus an additional six percent (6%) if and while there is an event of default by the Company under the Loan Agreement), with interest being payable monthly in arrears. The Company is entitled to make up to one draw per month under the Loan Agreement, and such amount cannot exceed the greater of (a) $1.7 million and (b) the monthly budgeted expense amount in the Company’s expense budget (which will be subject to agreement of the Company and Parkview) for the immediately subsequent month. Any unused borrowings from prior months may be added to the maximum borrowing permitted in the month in which a draw is being made by the Company. Assuming that the Company’s stockholders approve the issuance of the Loan Fee Shares (as defined below), the Company currently expects that the credit facility will provide the Company with sufficient access to capital to continue funding its operations and development programs into the first quarter of 2028 without regard to other sources of capital.

Under the Loan Agreement, if the Company achieves net profits in any fiscal quarter as a result of sales of pharmaceutical products for two consecutive fiscal quarters, the Company will be obligated to make repayments of principal under the Loan Agreement equal to 75% of such net profits from the previous fiscal quarter.

Under the Loan Agreement, the Company has also agreed to:

 

  •  

pursuant to a fee letter dated April 21, 2026 (the “Fee Letter”), pay a one-time loan commitment fee equal to ten percent (10%) of the total commitment under the Loan Agreement (resulting in a commitment fee of $5.0 million), which the Company has elected to pay by the issuance of an aggregate of 1,878,287 shares of Company common stock (the “Loan Fee Shares”) to Parkview based on a price equal to the average of the daily closing prices of the Company’s common stock during the ten trading days ending on (and including) April 21, 2026; provided that such shares shall be issued to Parkview only after and subject to the approval of such issuance by the Company’s stockholders at the next annual meeting of the Company’s stockholders, and in the absence of such approval by August 31, 2026, the commitment fee shall be due and payable in cash on September 1, 2026;

 

  •  

pay an annual cash facility fee, payable annually beginning on the first anniversary of the date of the Loan Agreement, equal to one and one-half percent (1.5%) of the total commitment; and

 

  •  

enter into two Warrant Amendment Agreements (the “Warrant Amendment Agreements”) to extend to April 21, 2031, the exercise period during which 4,364,873 of the Company’s warrants held by K&V Investment One, LLC, an affiliate of Parkview and Vijay Patel, may be exercised (3,049,432 of such warrants have an exercise price of $3.69 per share and 1,315,441 of such warrants have an exercise price of $5.70 per share, and such warrants constitute all of the Company warrants held by K&V Investment One LLC other than warrants issued in the Company’s registered direct offering which had its first closing on December 10, 2025).

The Loan Agreement contains various restrictions and covenants applicable to the Company and certain of its subsidiaries. Among other requirements, the Loan Agreement (a) limits the Company and its subsidiaries with respect to the incurrence or assumption of additional debt (subject to specified exceptions), (b) limits the Company’s permissible investments, dispositions and restricted payments, and (c) limits the Company in its ability to amend its organizational documents or material contracts.

The principal and accrued but unpaid interest in the Loan Agreement will not be convertible into common stock or other securities of the Company, other than in the case of a change of control of the Company in which a person or entity (other than Parkview, Vijay Patel, or their affiliates) acquires 51% or more of the outstanding equity interests in the Company (a “Change of Control”). Upon such a Change of Control, Parkview may, subject to the approval of such conversion right by the Company’s stockholders at a stockholder meeting prior to the Change of Control, convert all outstanding principal plus accrued and unpaid interest into shares of Company common stock (“Conversion Shares”) at a conversion price per share equal to $2.662.

The Loan Agreement also contains customary events of default, which include the occurrence of a Change of Control or the discontinuance of the Company’s development program for its IFx-20 product candidate. If an event of default under the Credit Agreement occurs and is continuing, then, among other things, Parkview may declare any outstanding obligations under the Loan Agreement to be immediately due and payable.

The Company may at any time prepay without penalty all or any portion of the amounts outstanding under the Loan Agreement, and the Company may elect at any time to terminate the Loan Agreement or reduce the amount Parkview’s loan commitment under the Loan Agreement.

In addition to the foregoing, pursuant to the Loan Agreement, the Company agreed that, if requested by Parkview, the Company would permit Parkview to appoint a director to the Company’s board of directors, subject to the rules and regulations of the Securities and Exchange Commission and any national securities exchange on which the Company’s shares of common stock are then listed.

In consideration of Parkview’s obligations under the Loan Agreement, the Company entered into a Royalty Agreement, dated April 21, 2026 (the “Royalty Agreement”), pursuant to which the Company granted to Parkview an annual royalty on sales by the Company and its sublicensees of products that incorporate or are based on the Company’s intellectual property covering IFx-2.0 (the “Products”). The royalty will be equal to a percentage of “Net Sales” (as defined in the Royalty Agreement) of Products up to $450 million in Net Sales per year, which percentage is in the low to mid-single digits range. The royalty payment obligation under the Royalty Agreement will continue through the last-to-expire patent covering IFx-2.0.

The foregoing descriptions of the Loan Agreement, Royalty Agreement, Fee Letter, and Warrant Amendment Agreements do not purport to be complete and are qualified in their entirety by reference to the full text of the Loan Agreement, Royalty Agreement, Fee Letter, and Warrant Amendment Agreements filed herewith as exhibits and incorporated herein by reference.

 

Item 2.03

Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

The information provided in Item 1.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 2.03.

 

Item 3.02

Unregistered Sales of Equity Securities

The disclosure in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.02. The Company claims an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), for the private placement of the Loan Fee Shares and Conversion Shares, as the Loan Fee Shares and Conversion Shares will be issued solely to “accredited investors,” as such term is defined in the Securities Act of 1933, as amended (the “Securities Act”), and in reliance on the exemption from registration afforded by Section 4(a)(2) and/or Regulation D (Rule 506) under the Securities Act and corresponding provisions of state securities laws.

 

Item 7.01

Regulation FD Disclosure.

On April 22, 2026, the Company issued a press release announcing the Loan Agreement and related matters. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated hereby reference.

The information contained in this Item 7.01 and in Exhibit 99.1 of this Current Report shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit
No

     
 4.1    Loan Agreement, dated April 21, 2026, by and between TuHURA Biosciences, Inc. and Parkview Holdings One LLC.
10.1*    Royalty Agreement, dated April 21, 2026, by and between TuHURA Biosciences, Inc. and Parkview Holdings One LLC.
10.2    Fee Letter, dated April 21, 2026, by and between TuHURA Biosciences, Inc. and Parkview Holdings One LLC.
10.3    Warrant Amendment Agreement (2022 Warrants), dated April 21, 2026, by and between TuHURA Biosciences, Inc. and K&V Investment One LLC.
10.4    Warrant Amendment Agreement (2024 Warrants), dated April 21, 2026, by and between TuHURA Biosciences, Inc. and K&V Investment One LLC.
99.1    Press Release, dated April 22, 2026.
104    Cover Page Interactive Data File (embedded within the inline XBRL document)

 

*

Confidential treatment is requested for portions of this exhibit that have been marked and omitted because the omitted information is both not material and is the type of information that the registrant treats as private or confidential pursuant to Item 601(b)(10)(iv) of Regulation S-K. The registrant undertakes to promptly provide an unredacted copy of the exhibit if requested by the Securities and Exchange Commission or its staff.

Forward-Looking Statements

This Current Report on Form 8-K contains certain “forward-looking statements” within the meaning of, and subject to the safe harbor created by Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based only on the Company’s current beliefs, expectations and assumptions regarding the future of the Company’s business, future plans and strategies, projections, anticipated events and other future conditions. In some cases, you can identify these statements by forward-looking words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “should,” “would,” “project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely,” or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding the Company’s expectations, hopes, beliefs, or intentions regarding: the Company’s ability to draw down sufficient funds against the Loan Agreement and the Company’s needs and expectations regarding existing and future capital resources and expenses and the Company’s need for additional capital. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include, among others: the risk that the Company may be unable to satisfy conditions to drawdown or maintain compliance with the terms of the Loan Agreement; the risk that funds available under the Loan Agreement may be insufficient to fund the Company’s operations and development programs to the extent anticipated; and potential conflicts of interest arising from the Loan Agreement with an affiliate of the Company’s largest stockholder; and the other risks described from time to time in detail in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed on March 31, 2026, and the Company’s other reports and filings with the SEC from time to time, which are available on the Company’s website and at www.sec.gov.

The forward-looking statements and other information contained in this Current Report on Form 8-K are made as of the date hereof, and the Company does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

      TUHURA BIOSCIENCES, INC.
Date: April 22, 2026     By:  

/s/ Dan Dearborn

    Name:   Dan Dearborn
    Title:   Chief Financial Officer

Exhibit 99.1

TuHURA Biosciences Announces $50 Million Credit Facility and Royalty Transaction Extending Anticipated Cash Runway into 2028

Credit facility anticipated to fund development of pipeline, including IFx-2.0 through Phase 3 results and TBS-2025 to key efficacy measurement milestones

TAMPA, Fla., April 22, 2026 — TuHURA Biosciences, Inc. (NASDAQ:HURA) (“TuHURA” or the “Company”), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that it has entered into a loan agreement providing a credit facility of up to $50 million in funding to support the Company’s pipeline, ongoing clinical trials, and general corporate expenses. The lender is an affiliate of the Company’s largest stockholder, K&V Investment One LLC.

Under the terms of the loan agreement, TuHURA will have the ability to draw down monthly on the facility on an as-needed basis to fund monthly expenses for ongoing clinical development and operations. The facility bears a 12% annual interest rate on outstanding funds drawn, with interest paid monthly and principal repayment due at a 5-year maturity date of April 21, 2031. The loan facility is secured by the assets of the Company and its subsidiaries. In connection with the credit facility, the Company granted the lender a low to mid-single digit percentage royalty on annual commercial sales by the Company or its sublicensees of products based on IFx-2.0.

“We are gratified to have established this non-equity based source of operating capital on what we believe are attractive terms for a company such as TuHURA. This agreement allows us to fund operations through anticipated key milestones this year and beyond through anticipated top-line Phase 3 results of our lead IFx-2.0 program. Importantly, we control the timing and amount of funds drawn under this facility while preserving the ability to be opportunistic in securing other potential sources of capital, including corporate partnerships or equity financings,” said Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences. “We believe that it is unusual to access such an attractive source of capital in advance of a BLA submission or pending FDA approval. This funding is a testament to the conviction our largest shareholder has in our strategy and in the potential for the clinical and commercial success of IFx-2.0.”

Additional information regarding the credit facility and royalty agreement, including the terms and provisions of the loan agreement, can be found in the Company’s Current Report on Form 8-K filed today with the Securities and Exchange Commission.

About TuHURA Biosciences, Inc.

TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.

TuHURA’s lead innate immune agonist, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA has initiated a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) compared to Keytruda® plus placebo in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

In addition to its innate immune agonist product candidates, TuHURA acquired TBS-2025 in its acquisition by merger with Kineta Inc. on June 30, 2025. TBS-2025 is a VISTA inhibiting mAb moving into Phase 1b/ 2 development in mutNPM1 r/r AML. In addition, TuHURA is leveraging its Delta Opioid Receptor technology to develop first-in-class, bi-specific, bi-functional antibody drug conjugates (ADCs) targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.

For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook, X, and LinkedIn.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains certain “forward-looking statements” within the meaning of, and subject to the safe harbor created by Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These Forward-Looking Statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and other future conditions. In some cases, you can identify these statements by forward-looking words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “could,” “should,” “would,” “project,” “plan,” “expect,” “goal,” “seek,” “future,” “likely,” or the negative or plural of these words or similar expressions. Examples of such forward-looking statements include, but are not limited to, express or implied statements regarding our expectations, hopes, beliefs, or intentions regarding: our ability to draw down sufficient funds against the above-described credit facility, our needs and expectations regarding

existing and future capital resources and expenses and our need for additional capital; the anticipated development, regulatory pathway and timing of our IFx-2.0 Phase 3 trial; the development of TBS-2025, our other technologies and product candidates; and the anticipated regulatory pathway and timing of the foregoing development programs, studies and trials. You are cautioned that such statements are not guarantees of future performance and that actual results or developments may differ materially from those set forth in these forward-looking statements. Factors that could cause actual results to differ materially from these forward-looking statements include, among others: the risk that the Company may be unable to satisfy conditions to drawdown or maintain compliance with the terms of the above-described credit facility; the risk that funds available under the credit facility may be insufficient to fund the Company’s operations and development programs to the extent anticipated; risks associated with conducting the ongoing Phase 3 trial for IFx.20; the risks associated with continuing the development of TBS-2025 and our DOR technologies; risks related to patient enrollment, trial design, data outcomes and regulatory interactions; uncertainty regarding the timing and likelihood of regulatory approvals; potential conflicts of interest arising from the credit facility with an affiliate of the Company’s largest stockholder, and the other risks described from time to time in detail in TuHURA’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, as filed on March 31, 2026, and TuHURA’s other reports and filings with the SEC from time to time, which are available on TuHURA’s website and at www.sec.gov.

The forward-looking statements and other information contained in this press release are made as of the date hereof, and TuHURA does not undertake any obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Investor Contact:

Monique Kosse

Gilmartin Group

Monique@GilmartinIR.com

Source: View Original Filing on SEC EDGAR

FAQ

What is the size and term of TuHURA Biosciences (HURA) new credit facility?

TuHURA secured a revolving credit facility of up to $50 million from Parkview Holdings One LLC. The facility matures on April 21, 2031, providing multi‑year access to debt capital to support operations and clinical development programs.

What interest rate does TuHURA Biosciences (HURA) pay on the new loan?

Borrowings under the facility bear interest at 12% per year, with an additional 6% if an event of default occurs and continues. Interest is payable monthly in arrears while principal is due at maturity or earlier repayment.

How long does TuHURA Biosciences expect the $50 million facility to fund operations?

Assuming stockholders approve issuance of related Loan Fee Shares, TuHURA currently expects the credit facility to provide sufficient capital to fund operations and development programs into the first quarter of 2028, independent of other potential funding sources.

What royalty did TuHURA Biosciences grant in connection with the credit facility?

TuHURA granted Parkview an annual royalty on Products based on IFx‑2.0 intellectual property. The royalty equals a low to mid‑single digit percentage of Net Sales on annual Product sales up to $450 million, lasting through the last‑to‑expire IFx‑2.0 patent.

Are there conversion rights associated with TuHURA Biosciences’ new loan?

If a qualifying Change of Control occurs, and stockholders have approved the conversion right, Parkview may convert all outstanding principal and accrued interest into common shares at $2.662 per share, rather than receiving cash repayment.

What covenants and restrictions are included in TuHURA Biosciences’ Loan Agreement?

The Loan Agreement limits TuHURA’s ability to incur additional debt, make certain investments, dispositions and restricted payments, and to amend organizational documents or material contracts. It also includes customary events of default, including certain changes of control and discontinuation of the IFx‑2.0 development program.

Filing Exhibits & Attachments

9 documents

Press Releases

Agreements & Contracts

Other Documents